WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - October 18, 2016) - Clinical Ink®, the leading provider of eSource and mobile patient engagement technologies for clinical trials, announces the addition of Kirk McPoyle to its management team. He has joined Clinical Ink as the Chief Commercial Officer.
"Kirk has an excellent track record of driving growth within the clinical research field," said CEO Ed Seguine. "His therapeutic area insights and consultative approach are perfectly in line with our strengths in improving protocol execution and process improvements within clinical trials. We're excited for him to help support new and existing clients for Clinical Ink."
Mr. McPoyle brings 25 years of business development and marketing experience to Clinical Ink. A seasoned veteran of the clinical research world, Mr. McPoyle most recently led Business Development at Acurian, where he created strategic opportunities for the company to maintain a dynamic revenue growth for ten years. McPoyle will bring this experience to one of the fastest growing companies in the life sciences arena. With its second consecutive inclusion in the INC 5000, Clinical Ink has been recognized as one of the fastest growing companies in the U.S.
Mr. McPoyle has experience with CROs, patient recruitment, business intelligence technology and pharmaceutical companies. His commercial operations and business development knowledge are a welcome addition to an already solid team and organization. "Over the years, I've seen a lot of industry change. Clinical Ink offers the most compelling and innovative clinical technology platform I've seen in this market. They've grown quickly and established a solid customer base in both large and small pharma, and I'm excited to help accelerate this growth."
Mr. McPoyle joins Clinical Ink during a period of major expansion. Since its commercial launch in 2012, Clinical Ink has emerged as an industry leader with its direct eSource and patient engagement platform that supports and generates innovation in clinical trials. The SureSource platform eliminates the need for separate EDC, eCOA, and ePRO applications which reduces trial complexity, cost, and development time. SureSource collects documents and data from sites and patients in real time, providing sponsors with timely, data-based insights into quality, protocol execution, and compliance that are impossible with legacy EDC/eCOA/ePRO systems and current practices.
About Clinical Ink
Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink's SureSource® platform directly captures eSource data and documents and improves patient engagement while streamlining clinical development. Clinical Ink maintains offices in Cambridge, MA, Winston-Salem, NC, and Philadelphia, PA. Find more at www.clinicalink.com.